Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 66

1.

miR-31-3p Expression and Benefit from Anti-EGFR Inhibitors in Metastatic Colorectal Cancer Patients Enrolled in the Prospective Phase II PROSPECT-C Trial.

Anandappa G, Lampis A, Cunningham D, Khan KH, Kouvelakis K, Vlachogiannis G, Hedayat S, Tunariu N, Rao S, Watkins D, Starling N, Braconi C, Darvish-Damavandi M, Lote H, Thomas J, Peckitt C, Kalaitzaki R, Khan N, Fotiadis N, Rugge M, Begum R, Rana I, Bryant A, Hahne JC, Chau I, Fassan M, Valeri N.

Clin Cancer Res. 2019 Apr 5. doi: 10.1158/1078-0432.CCR-18-3769. [Epub ahead of print]

PMID:
30952636
2.

Genomic loss of heterozygosity and survival in the REAL3 trial.

Smyth EC, Cafferkey C, Loehr A, Waddell T, Begum R, Peckitt C, Harding TC, Nguyen M, Okines AF, Raponi M, Rao S, Watkins D, Starling N, Middleton GW, Wadsley J, Mansoor W, Crosby T, Wotherspoon A, Chau I, Cunningham D.

Oncotarget. 2018 Nov 30;9(94):36654-36665. doi: 10.18632/oncotarget.26336. eCollection 2018 Nov 30.

3.

Longitudinal Liquid Biopsy and Mathematical Modeling of Clonal Evolution Forecast Time to Treatment Failure in the PROSPECT-C Phase II Colorectal Cancer Clinical Trial.

Khan KH, Cunningham D, Werner B, Vlachogiannis G, Spiteri I, Heide T, Mateos JF, Vatsiou A, Lampis A, Damavandi MD, Lote H, Huntingford IS, Hedayat S, Chau I, Tunariu N, Mentrasti G, Trevisani F, Rao S, Anandappa G, Watkins D, Starling N, Thomas J, Peckitt C, Khan N, Rugge M, Begum R, Hezelova B, Bryant A, Jones T, Proszek P, Fassan M, Hahne JC, Hubank M, Braconi C, Sottoriva A, Valeri N.

Cancer Discov. 2018 Oct;8(10):1270-1285. doi: 10.1158/2159-8290.CD-17-0891. Epub 2018 Aug 30.

4.

Rapid access clinic for unexplained lymphadenopathy and suspected malignancy: prospective analysis of 1000 patients.

Kühnl A, Cunningham D, Hutka M, Peckitt C, Rozati H, Morano F, Chong I, Gillbanks A, Wotherspoon A, Harris M, Murray T, Chau I.

BMC Hematol. 2018 Aug 14;18:19. doi: 10.1186/s12878-018-0109-0. eCollection 2018.

5.

PATRIOT: A phase I study to assess the tolerability, safety and biological effects of a specific ataxia telangiectasia and Rad3-related (ATR) inhibitor (AZD6738) as a single agent and in combination with palliative radiation therapy in patients with solid tumours.

Dillon MT, Boylan Z, Smith D, Guevara J, Mohammed K, Peckitt C, Saunders M, Banerji U, Clack G, Smith SA, Spicer JF, Forster MD, Harrington KJ.

Clin Transl Radiat Oncol. 2018 Jun 8;12:16-20. doi: 10.1016/j.ctro.2018.06.001. eCollection 2018 Aug.

6.

Survival in Advanced Esophagogastric Adenocarcinoma Improves With Use of Multiple Lines of Therapy: Results From an Analysis of More Than 500 Patients.

Davidson M, Cafferkey C, Goode EF, Kouvelakis K, Hughes D, Reguera P, Kalaitzaki E, Peckitt C, Rao S, Watkins D, Chau I, Cunningham D, Starling N.

Clin Colorectal Cancer. 2018 Sep;17(3):223-230. doi: 10.1016/j.clcc.2018.05.014. Epub 2018 Jun 8.

PMID:
29980492
7.

CHOP versus GEM-P in previously untreated patients with peripheral T-cell lymphoma (CHEMO-T): a phase 2, multicentre, randomised, open-label trial.

Gleeson M, Peckitt C, To YM, Edwards L, Oates J, Wotherspoon A, Attygalle AD, Zerizer I, Sharma B, Chua S, Begum R, Chau I, Johnson P, Ardeshna KM, Hawkes EA, Macheta MP, Collins GP, Radford J, Forbes A, Hart A, Montoto S, McKay P, Benstead K, Morley N, Kalakonda N, Hasan Y, Turner D, Cunningham D.

Lancet Haematol. 2018 May;5(5):e190-e200. doi: 10.1016/S2352-3026(18)30039-5.

8.

Investigating the feasibility of tumour molecular profiling in gastrointestinal malignancies in routine clinical practice.

Moorcraft SY, Gonzalez de Castro D, Cunningham D, Jones T, Walker BA, Peckitt C, Yuan LC, Frampton M, Begum R, Eltahir Z, Wotherspoon A, Teixeira Mendes LS, Hulkki Wilson S, Gillbanks A, Baratelli C, Fotiadis N, Patel A, Braconi C, Valeri N, Gerlinger M, Rao S, Watkins D, Chau I, Starling N.

Ann Oncol. 2018 Jan 1;29(1):230-236. doi: 10.1093/annonc/mdx631.

PMID:
29361134
9.

Treatment and Survival Outcome of BRAF-Mutated Metastatic Colorectal Cancer: A Retrospective Matched Case-Control Study.

Kayhanian H, Goode E, Sclafani F, Ang JE, Gerlinger M, Gonzalez de Castro D, Shepherd S, Peckitt C, Rao S, Watkins D, Chau I, Cunningham D, Starling N.

Clin Colorectal Cancer. 2018 Mar;17(1):e69-e76. doi: 10.1016/j.clcc.2017.10.006. Epub 2017 Oct 16.

PMID:
29129559
10.

Outcomes following front-line chemotherapy in peripheral T-cell lymphoma: 10-year experience at The Royal Marsden and The Christie Hospital.

Gleeson M, Peckitt C, Cunningham D, Gibb A, Hawkes EA, Back M, Yasar B, Foley K, Lee R, Dash J, Johnson H, O'Hara C, Wotherspoon A, Attygalle A, Menasce L, Shenjere P, Potter M, Ethell ME, Dearden C, Radford J, Chau I, Linton K.

Leuk Lymphoma. 2018 Jul;59(7):1586-1595. doi: 10.1080/10428194.2017.1393671. Epub 2017 Nov 9.

PMID:
29119842
11.

Pharmacogenetic Analysis of the UK MRC (Medical Research Council) MAGIC Trial: Association of Polymorphisms with Toxicity and Survival in Patients Treated with Perioperative Epirubicin, Cisplatin, and 5-fluorouracil (ECF) Chemotherapy.

Smyth E, Zhang S, Cunningham D, Wotherspoon A, Soong R, Peckitt C, Valeri N, Fassan M, Rugge M, Okines A, Allum W, Stenning S, Nankivell M, Langley R, Tan P.

Clin Cancer Res. 2017 Dec 15;23(24):7543-7549. doi: 10.1158/1078-0432.CCR-16-3142. Epub 2017 Oct 2.

12.

Comparison between MRI and pathology in the assessment of tumour regression grade in rectal cancer.

Sclafani F, Brown G, Cunningham D, Wotherspoon A, Mendes LST, Balyasnikova S, Evans J, Peckitt C, Begum R, Tait D, Tabernero J, Glimelius B, Roselló S, Thomas J, Oates J, Chau I.

Br J Cancer. 2017 Nov 7;117(10):1478-1485. doi: 10.1038/bjc.2017.320. Epub 2017 Sep 21.

13.

The prevalence of unmet needs in 625 women living beyond a diagnosis of early breast cancer.

Capelan M, Battisti NML, McLoughlin A, Maidens V, Snuggs N, Slyk P, Peckitt C, Ring A.

Br J Cancer. 2017 Oct 10;117(8):1113-1120. doi: 10.1038/bjc.2017.283. Epub 2017 Aug 31.

14.

Mismatch Repair Deficiency, Microsatellite Instability, and Survival: An Exploratory Analysis of the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) Trial.

Smyth EC, Wotherspoon A, Peckitt C, Gonzalez D, Hulkki-Wilson S, Eltahir Z, Fassan M, Rugge M, Valeri N, Okines A, Hewish M, Allum W, Stenning S, Nankivell M, Langley R, Cunningham D.

JAMA Oncol. 2017 Sep 1;3(9):1197-1203. doi: 10.1001/jamaoncol.2016.6762.

15.

Outcomes for transformed follicular lymphoma in the rituximab era: the Royal Marsden experience 2003-2013.

Gleeson M, Hawkes EA, Peckitt C, Wotherspoon A, Attygalle A, Sharma B, Du Y, Ethell M, Potter M, Dearden C, Horwich A, Chau I, Cunningham D.

Leuk Lymphoma. 2017 Aug;58(8):1805-1813. doi: 10.1080/10428194.2016.1265114. Epub 2016 Dec 8.

PMID:
27931133
16.

Attitudes of Patients With Gastrointestinal Cancers Toward Research Biopsies.

Moorcraft SY, Begum R, Cunningham D, Peckitt C, Baratelli C, Gillbanks A, Rogers P, Nwokorie V, Chau I, Watkins D, Starling N.

Clin Colorectal Cancer. 2017 Sep;16(3):e181-e189. doi: 10.1016/j.clcc.2016.09.008. Epub 2016 Oct 6.

PMID:
27839727
17.

Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases.

Frentzas S, Simoneau E, Bridgeman VL, Vermeulen PB, Foo S, Kostaras E, Nathan M, Wotherspoon A, Gao ZH, Shi Y, Van den Eynden G, Daley F, Peckitt C, Tan X, Salman A, Lazaris A, Gazinska P, Berg TJ, Eltahir Z, Ritsma L, Van Rheenen J, Khashper A, Brown G, Nystrom H, Sund M, Van Laere S, Loyer E, Dirix L, Cunningham D, Metrakos P, Reynolds AR.

Nat Med. 2016 Nov;22(11):1294-1302. doi: 10.1038/nm.4197. Epub 2016 Oct 17.

18.

Dalotuzumab in chemorefractory KRAS exon 2 mutant colorectal cancer: Results from a randomised phase II/III trial.

Sclafani F, Kim TY, Cunningham D, Kim TW, Tabernero J, Schmoll HJ, Roh JK, Kim SY, Park YS, Guren TK, Hawkes E, Clarke SJ, Ferry D, Frodin JE, Ayers M, Nebozhyn M, Peckitt C, Loboda A, Watkins DJ.

Int J Cancer. 2017 Jan 15;140(2):431-439. doi: 10.1002/ijc.30453. Epub 2016 Oct 17.

19.

A study of motivations and expectations of patients seen in phase 1 oncology clinics.

Dolly SO, Kalaitzaki E, Puglisi M, Stimpson S, Hanwell J, Fandos SS, Stapleton S, Ansari T, Peckitt C, Kaye S, Lopez J, Yap TA, van der Graaf W, de Bono J, Banerji U.

Cancer. 2016 Nov 15;122(22):3501-3508. doi: 10.1002/cncr.30235. Epub 2016 Sep 26.

20.

Sequence variation in mature microRNA-608 and benefit from neo-adjuvant treatment in locally advanced rectal cancer patients.

Sclafani F, Chau I, Cunningham D, Lampis A, Hahne JC, Ghidini M, Lote H, Zito D, Tabernero J, Glimelius B, Cervantes A, Begum R, De Castro DG, Wilson SH, Peckitt C, Eltahir Z, Wotherspoon A, Tait D, Brown G, Oates J, Braconi C, Valeri N.

Carcinogenesis. 2016 Sep;37(9):852-7. doi: 10.1093/carcin/bgw073. Epub 2016 Jul 5.

21.

Effect of Pathologic Tumor Response and Nodal Status on Survival in the Medical Research Council Adjuvant Gastric Infusional Chemotherapy Trial.

Smyth EC, Fassan M, Cunningham D, Allum WH, Okines AF, Lampis A, Hahne JC, Rugge M, Peckitt C, Nankivell M, Langley R, Ghidini M, Braconi C, Wotherspoon A, Grabsch HI, Valeri N.

J Clin Oncol. 2016 Aug 10;34(23):2721-7. doi: 10.1200/JCO.2015.65.7692. Epub 2016 Jun 13.

22.

PAN-EX: a pooled analysis of two trials of neoadjuvant chemotherapy followed by chemoradiotherapy in MRI-defined, locally advanced rectal cancer.

Sclafani F, Brown G, Cunningham D, Wotherspoon A, Tait D, Peckitt C, Evans J, Yu S, Sena Teixeira Mendes L, Tabernero J, Glimelius B, Cervantes A, Thomas J, Begum R, Oates J, Chau I.

Ann Oncol. 2016 Aug;27(8):1557-65. doi: 10.1093/annonc/mdw215. Epub 2016 May 23.

PMID:
27217542
23.

High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical Trial.

Pearson A, Smyth E, Babina IS, Herrera-Abreu MT, Tarazona N, Peckitt C, Kilgour E, Smith NR, Geh C, Rooney C, Cutts R, Campbell J, Ning J, Fenwick K, Swain A, Brown G, Chua S, Thomas A, Johnston SRD, Ajaz M, Sumpter K, Gillbanks A, Watkins D, Chau I, Popat S, Cunningham D, Turner NC.

Cancer Discov. 2016 Aug;6(8):838-851. doi: 10.1158/2159-8290.CD-15-1246. Epub 2016 May 13.

24.

Characterising timing and pattern of relapse following surgery for localised oesophagogastric adenocarcinoma: a retrospective study.

Moorcraft SY, Fontana E, Cunningham D, Peckitt C, Waddell T, Smyth EC, Allum W, Thompson J, Rao S, Watkins D, Starling N, Chau I.

BMC Cancer. 2016 Feb 17;16:112. doi: 10.1186/s12885-016-2145-0.

25.

miR-21 expression and clinical outcome in locally advanced pancreatic cancer: exploratory analysis of the pancreatic cancer Erbitux, radiotherapy and UFT (PERU) trial.

Khan K, Cunningham D, Peckitt C, Barton S, Tait D, Hawkins M, Watkins D, Starling N, Rao S, Begum R, Thomas J, Oates J, Guzzardo V, Fassan M, Braconi C, Chau I.

Oncotarget. 2016 Mar 15;7(11):12672-81. doi: 10.18632/oncotarget.7208.

26.

Does cancer research focus on areas of importance to patients?

Moorcraft SY, Sangha A, Peckitt C, Sanchez R, Lee M, Pattison N, Wiseman T.

Ecancermedicalscience. 2016 Jan 7;10:ed51. doi: 10.3332/ecancer.2016.ed51. eCollection 2016.

27.

Prognostic value of neutrophil-to-lymphocyte ratio in advanced oesophago-gastric cancer: exploratory analysis of the REAL-2 trial.

Grenader T, Waddell T, Peckitt C, Oates J, Starling N, Cunningham D, Bridgewater J.

Ann Oncol. 2016 Apr;27(4):687-92. doi: 10.1093/annonc/mdw012. Epub 2016 Jan 19.

PMID:
26787231
28.

Response.

Sclafani F, Cunningham D, Peckitt C, Watkins D.

J Natl Cancer Inst. 2016 Jan 11;108(3). pii: djv405. doi: 10.1093/jnci/djv405. Print 2016 Mar. No abstract available.

PMID:
26754850
29.

Exclusion of Gastrointestinal Cancer Patients With Prior Cancer From Clinical Trials: Is This Justified?

Smyth EC, Tarazona N, Peckitt C, Armstrong E, Mansukhani S, Cunningham D, Chau I.

Clin Colorectal Cancer. 2016 Jun;15(2):e53-9. doi: 10.1016/j.clcc.2015.11.003. Epub 2015 Nov 27.

PMID:
26747392
30.

Patients' willingness to participate in clinical trials and their views on aspects of cancer research: results of a prospective patient survey.

Moorcraft SY, Marriott C, Peckitt C, Cunningham D, Chau I, Starling N, Watkins D, Rao S.

Trials. 2016 Jan 9;17:17. doi: 10.1186/s13063-015-1105-3.

31.

The influence of industry sponsorship on the reporting of subgroup analyses within phase III randomised controlled trials in gastrointestinal oncology.

Barton S, Peckitt C, Sclafani F, Cunningham D, Chau I.

Eur J Cancer. 2015 Dec;51(18):2732-9. doi: 10.1016/j.ejca.2015.08.030. Epub 2015 Nov 19. Review.

PMID:
26608121
32.

Improved survival in resected oesophageal and gastric adenocarcinomas over a decade: the Royal Marsden experience 2001-2010.

Fontana E, Smyth EC, Cunningham D, Rao S, Watkins D, Allum WH, Thompson J, Waddell T, Peckitt C, Chau I, Starling N.

Gastric Cancer. 2016 Oct;19(4):1114-1124. doi: 10.1007/s10120-015-0561-5. Epub 2015 Nov 5.

PMID:
26541768
33.

A Randomized Phase II/III Study of Dalotuzumab in Combination With Cetuximab and Irinotecan in Chemorefractory, KRAS Wild-Type, Metastatic Colorectal Cancer.

Sclafani F, Kim TY, Cunningham D, Kim TW, Tabernero J, Schmoll HJ, Roh JK, Kim SY, Park YS, Guren TK, Hawkes E, Clarke SJ, Ferry D, Frödin JE, Ayers M, Nebozhyn M, Peckitt C, Loboda A, Mauro DJ, Watkins DJ.

J Natl Cancer Inst. 2015 Sep 23;107(12):djv258. doi: 10.1093/jnci/djv258. Print 2015 Dec.

PMID:
26405092
34.

Prognostic role of the LCS6 KRAS variant in locally advanced rectal cancer: results of the EXPERT-C trial.

Sclafani F, Chau I, Cunningham D, Peckitt C, Lampis A, Hahne JC, Braconi C, Tabernero J, Glimelius B, Cervantes A, Begum R, Gonzalez De Castro D, Hulkki Wilson S, Eltahir Z, Wotherspoon A, Tait D, Brown G, Oates J, Valeri N.

Ann Oncol. 2015 Sep;26(9):1936-41. doi: 10.1093/annonc/mdv285. Epub 2015 Jul 10.

35.

Short- and Long-Term Quality of Life and Bowel Function in Patients With MRI-Defined, High-Risk, Locally Advanced Rectal Cancer Treated With an Intensified Neoadjuvant Strategy in the Randomized Phase 2 EXPERT-C Trial.

Sclafani F, Peckitt C, Cunningham D, Tait D, Giralt J, Glimelius B, Keränen SR, Bateman A, Hickish T, Tabernero J, Thomas J, Brown G, Oates J, Chau I.

Int J Radiat Oncol Biol Phys. 2015 Oct 1;93(2):303-12. doi: 10.1016/j.ijrobp.2015.03.038. Epub 2015 Apr 4.

PMID:
26031368
36.

Prognostic factors and treatment outcomes in patients with Small Bowel Adenocarcinoma (SBA): the Royal Marsden Hospital (RMH) experience.

Khan K, Peckitt C, Sclafani F, Watkins D, Rao S, Starling N, Jain V, Trivedi S, Stanway S, Cunningham D, Chau I.

BMC Cancer. 2015 Jan 21;15:15. doi: 10.1186/s12885-015-1014-6.

37.

Clinical trial designs for rare diseases: studies developed and discussed by the International Rare Cancers Initiative.

Bogaerts J, Sydes MR, Keat N, McConnell A, Benson A, Ho A, Roth A, Fortpied C, Eng C, Peckitt C, Coens C, Pettaway C, Arnold D, Hall E, Marshall E, Sclafani F, Hatcher H, Earl H, Ray-Coquard I, Paul J, Blay JY, Whelan J, Panageas K, Wheatley K, Harrington K, Licitra L, Billingham L, Hensley M, McCabe M, Patel PM, Carvajal R, Wilson R, Glynne-Jones R, McWilliams R, Leyvraz S, Rao S, Nicholson S, Filiaci V, Negrouk A, Lacombe D, Dupont E, Pauporté I, Welch JJ, Law K, Trimble T, Seymour M.

Eur J Cancer. 2015 Feb;51(3):271-81. doi: 10.1016/j.ejca.2014.10.027. Epub 2014 Dec 24. Review.

38.

FOLFIRINOX for locally advanced or metastatic pancreatic ductal adenocarcinoma: the Royal Marsden experience.

Moorcraft SY, Khan K, Peckitt C, Watkins D, Rao S, Cunningham D, Chau I.

Clin Colorectal Cancer. 2014 Dec;13(4):232-8. doi: 10.1016/j.clcc.2014.09.005. Epub 2014 Sep 21.

PMID:
25442814
39.

Rituximab, Gemcitabine, Cisplatin and Methylprednisolone (R-GEM-P) is an effective regimen in relapsed diffuse large B-cell lymphoma.

Barton S, Hawkes EA, Cunningham D, Peckitt C, Chua S, Wotherspoon A, Attygalle A, Horwich A, Potter M, Ethell M, Dearden C, Gleeson M, Chau I.

Eur J Haematol. 2015 Mar;94(3):219-26. doi: 10.1111/ejh.12416. Epub 2014 Aug 18.

PMID:
25039915
40.

FcγRIIa and FcγRIIIa polymorphisms and cetuximab benefit in the microscopic disease.

Sclafani F, Gonzalez de Castro D, Cunningham D, Hulkki Wilson S, Peckitt C, Capdevila J, Glimelius B, Roselló Keränen S, Wotherspoon A, Brown G, Tait D, Begum R, Thomas J, Oates J, Chau I.

Clin Cancer Res. 2014 Sep 1;20(17):4511-9. doi: 10.1158/1078-0432.CCR-14-0674. Epub 2014 Jul 1.

41.

TP53 mutational status and cetuximab benefit in rectal cancer: 5-year results of the EXPERT-C trial.

Sclafani F, Gonzalez D, Cunningham D, Hulkki Wilson S, Peckitt C, Tabernero J, Glimelius B, Cervantes A, Dewdney A, Wotherspoon A, Brown G, Tait D, Oates J, Chau I.

J Natl Cancer Inst. 2014 Jun 23;106(7). pii: dju121. doi: 10.1093/jnci/dju121. Print 2014 Jul.

PMID:
24957073
42.

RAS mutations and cetuximab in locally advanced rectal cancer: results of the EXPERT-C trial.

Sclafani F, Gonzalez D, Cunningham D, Hulkki Wilson S, Peckitt C, Giralt J, Glimelius B, Roselló Keränen S, Wotherspoon A, Brown G, Tait D, Oates J, Chau I.

Eur J Cancer. 2014 May;50(8):1430-6. doi: 10.1016/j.ejca.2014.02.002. Epub 2014 Feb 28.

PMID:
24582914
43.

GEM-P chemotherapy is active in the treatment of relapsed Hodgkin lymphoma.

Hawkes EA, Barton S, Cunningham D, Peckitt C, Chua S, Wotherspoon A, Horwich A, Potter M, Ethel M, Dearden C, Chau I.

Ann Hematol. 2014 May;93(5):827-34. doi: 10.1007/s00277-013-1930-y. Epub 2013 Oct 26.

PMID:
24158386
44.

HER2 in high-risk rectal cancer patients treated in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab.

Sclafani F, Roy A, Cunningham D, Wotherspoon A, Peckitt C, Gonzalez de Castro D, Tabernero J, Glimelius B, Cervantes A, Eltahir Z, Oates J, Chau I.

Ann Oncol. 2013 Dec;24(12):3123-8. doi: 10.1093/annonc/mdt408. Epub 2013 Oct 20.

PMID:
24146218
45.

Patupilone in patients with pretreated metastatic/locally recurrent colorectal cancer: results of the Phase II CINATRA trial.

Moorcraft SY, Chau I, Peckitt C, Cunningham D, Rao S, Yim KL, Walther A, Jackson CG, Stamp G, Webb J, Smith G, Gillbanks A, Swanton C.

Invest New Drugs. 2013 Oct;31(5):1339-44. doi: 10.1007/s10637-013-9990-3. Epub 2013 Jun 26.

PMID:
23801302
46.

Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial.

Waddell T, Chau I, Cunningham D, Gonzalez D, Okines AF, Okines C, Wotherspoon A, Saffery C, Middleton G, Wadsley J, Ferry D, Mansoor W, Crosby T, Coxon F, Smith D, Waters J, Iveson T, Falk S, Slater S, Peckitt C, Barbachano Y.

Lancet Oncol. 2013 May;14(6):481-9. doi: 10.1016/S1470-2045(13)70096-2. Epub 2013 Apr 15. Erratum in: Lancet Oncol. 2013 Jun;14(7):e254. Frances, Alicia [corrected to Okines, Alicia Frances Clare].

47.

Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double-blind comparison.

Mahler DA, D'Urzo A, Bateman ED, Ozkan SA, White T, Peckitt C, Lassen C, Kramer B; INTRUST-1 and INTRUST-2 study investigators.

Thorax. 2012 Sep;67(9):781-8. Epub 2012 Apr 27.

PMID:
22544891
48.

Oral corticosteroid sparing with omalizumab in severe allergic (IgE-mediated) asthma patients.

Siergiejko Z, Świebocka E, Smith N, Peckitt C, Leo J, Peachey G, Maykut R.

Curr Med Res Opin. 2011 Nov;27(11):2223-8. doi: 10.1185/03007995.2011.620950. Epub 2011 Sep 21.

PMID:
21933100
49.

Delivery characteristics and patients' handling of two single-dose dry-powder inhalers used in COPD.

Chapman KR, Fogarty CM, Peckitt C, Lassen C, Jadayel D, Dederichs J, Dalvi M, Kramer B.

Int J Chron Obstruct Pulmon Dis. 2011;6:353-63. doi: 10.2147/COPD.S18529. Epub 2011 Jun 23.

50.

Persistency of response to omalizumab therapy in severe allergic (IgE-mediated) asthma.

Bousquet J, Siergiejko Z, Swiebocka E, Humbert M, Rabe KF, Smith N, Leo J, Peckitt C, Maykut R, Peachey G.

Allergy. 2011 May;66(5):671-8. doi: 10.1111/j.1398-9995.2010.02522.x. Epub 2011 Jan 21.

PMID:
21255035

Supplemental Content

Loading ...
Support Center